THERAMEX
A new international survey of 1,008 women with osteoporosis from six countries, launched on World Osteoporosis Day, reveals that while more than two-thirds (67%) of women over the age of 55 mostly understand what osteoporosis is and the potential negative impact of future fractures, 19% felt poorly informed at the time of the diagnosis.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005894/en/
The survey initiated by Theramex in cooperation with the International Osteoporosis Foundation (IOF), was conducted in Germany, France, Italy, Spain, Australia, and Brazil. It included 316 postmenopausal women over the age of 55 years and 315 premenopausal women (40-55 years) with osteoporosis (altogether 62% of the surveyed women). Of these women, osteoporosis was only diagnosed after a fracture in almost 60% of the cases. This survey highlights a gap in osteoporosis awareness, as one-fourth of the patients aged 55 years and over were not aware and did not understand the link between osteoporosis and bone fractures.1 A third (35%) of respondents said they would have been motivated to watch out for their bone health if they had known that one in three women aged over 50 will suffer a fragility fracture, but fragility fractures are preventable with the right treatment.1,2 In addition, close to 25% of postmenopausal women felt not listened to by their doctors when discussing their treatment.1
Osteoporosis is a chronic condition causing loss of bone mass and strength, resulting in fragile bones.3 It is a growing problem,3 affecting around 500 million people globally.4 Osteoporosis affects more women than men, with the risk increasing with age.5 Women are at higher risk of osteoporosis after the menopause, when the ovaries stop producing oestrogen, a hormone which has a protective effect on bones.5
Dr. Philippe Halbout, International Osteoporosis Foundation CEO said, “The impact of osteoporosis should not be underestimated. Fractures can be life-altering, causing pain, disability and loss of independence which is why it’s so important to ensure that patients are receiving the information, care and treatment they need to manage their condition and prevent or delay fractures. This survey highlights the need for improved doctor-patient communications and demonstrates the importance of education to empower women to ask for more from their care.”
Theramex CEO, Robert Stewart, commented, “Women with osteoporosis deserve support and appropriate treatment to help them continue to enjoy their lifestyles and precious moments with loved ones. We are committed to working with the osteoporosis community to provide accessible information and education about the condition, as the more women know and understand, the more they will be empowered to ask for more from their osteoporosis care, helping to reduce or eliminate the risk of fractures.”
This World Osteoporosis Day, women are being urged to #askformore from their osteoporosis care and treatment. For further information and osteoporosis resources, visit www.worldosteoporosisday.org
ENDS
NOTES TO EDITOR:
About the survey1
The online survey was conducted among 1,008 women with osteoporosis across six countries: Germany (73), France (74), Spain (122), Italy (298), Australia (54) and Brazil (387). The respondents were all female with 377 under 40, 315 aged 40-54, 201 aged 55-64, 90 aged 65-75 and 25 over 75. It should be noted that the risk of osteoporosis increases with age, despite the number of women in the younger age category in this survey. The survey was conducted between 5 – 12 July 2021 by Opinion Matters on behalf of Theramex.
About Osteoporosis
Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.
- It is a significant health issue – affecting ~500 million people worldwide4
- Osteoporosis affects more women than men and risk increase with age5
- After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy5
- One in three women aged over 50 will suffer a fragility fracture2
- Hip, spine, and wrist fractures are the most common fractures in osteoporosis and have a debilitating impact on daily activities and quality of life2
- After a spine fracture, mortality is increased immediately after the fracture event6
- Spine fractures can lead to back pain, loss of height, deformity, immobility, impaired quality of life (QoL), and difficulties in activities of daily living7,8,9
About the International Osteoporosis Foundation (IOF)
The International Osteoporosis Foundation is the world’s largest non-governmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases.
IOF Vision
Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.
IOF Mission
To promote bone and musculoskeletal health as a worldwide priority.
About Theramex
Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.
References:
- Opinion Matters. (2021) #Askformore Osteoporosis International Survey.
- Cooper, C. (2019) IOF Compendium of Osteoporosis . IOF. 2nd edition.
- Noh, J.Y., Yang, Y. & Jung, H. (2020) Int J Mol Sci. 21 (20), 7623
- IOF. (n.d.) IOF website Facts and Statistics https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Accessed 18th October 2021]
- IOF. (n.d.) About Osteoporosis: Risk Factors. Available from: https://www.osteoporosis.foundation/patients/about-osteoporosis/risk-factors [Accessed 18th October 2021]
- Johnell, O. et al. (2004) Osteoporos Int 15 (1), 38-42.
- Nevitt, M.C. et al. (1998) Ann Intern Med 128 (10), 793-800.
- Lips, P. et al (1999) Osteoporos Int 10, 150-160.
- Tosteson, A.N. et al (2001) Osteoporos Int 12:1042-1049.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005894/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Unveils Advanced Matter over Thread Modules for Seamless Device Interoperability13.11.2025 10:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announced the launch of the KGM133S, the first in a range of Matter over Thread modules that provides innovative solutions for applications such as smart door locks, sensors, and lighting, helping the smart home industry overcome connectivity barriers and advance toward a new era of more efficient and seamless development. The KGM133S series modules are built based on the Silicon Labs EFR32MG24 chip, supporting the latest Matter 1.4 protocol. The modules are designed to enable seamless linkage of home devices across ecosystems, including Apple Home, Google Home, Amazon Alexa and Samsung SmartThings. “Protocol fragmentation remains one of the biggest obstacles to seamless smart device connectivity, and the Matter protocol is the key to overcoming it,” said Delbert Sun, Deputy General Manager at Quectel Wireless Solutions. “With our new Matter over Thread modules, we are helping the industry achieve true inter
SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 09:57:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).
IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 09:56:00 CET | Press release
IQM Halocene is a new quantum computer product line aimed at error correction development. It will start with a150-qubit system to be delivered by the end of 2026 and extend all the way to 1,000-qubits. The new product line is based on an open and modular error correction stack, which will allow end-users to experiment and run different quantum error correction features. IQM’s goal is to enable users from supercomputing centers, research organizations, and universities to innovate on quantum error correction research with an open platform. IQM has sold more on-premises quantum systems globally than any other manufacturer, and the company expects the new Halocene product line to accelerate its revenue growth further IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research
JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 09:45:00 CET | Press release
Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discover
Ohmium Breaks Barriers: Exceeds 2030 Industry Targets of 10 GW/ton to Achieve 18 GW/ton Iridium Utilization13.11.2025 09:05:00 CET | Press release
Ohmium International Inc., a leading provider of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has surpassed the PEM electrolyzer industry's 2030 target of 10 GW per ton to attain an 18 GW per ton iridium utilization rate. Ohmium has made significant technological advancements which have resulted in reducing its iridium usage by 50% in its Lotus electrolyzer, Mark 2. This enhances the cost-competitiveness of green hydrogen production by reducing the overall cost of its PEM electrolyzers, which have been impacted by the cost of the precious metal, iridium. Dr. Chock Karuppaiah, Ohmium Chief Science and Technology Officer, said, "We've made significant strides in reducing iridium usage in our PEM electrolyzers, exceeding the 2030 industry target of 10 GW per ton. We've achieved a utilization rate of 18 GW per ton. This innovation is crucial, as iridium is one of the most expensive materials in electrolyzer manufacturing.” Dr. Markus Tacke, Ohmiu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
